JP2007512299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007512299A5 JP2007512299A5 JP2006540603A JP2006540603A JP2007512299A5 JP 2007512299 A5 JP2007512299 A5 JP 2007512299A5 JP 2006540603 A JP2006540603 A JP 2006540603A JP 2006540603 A JP2006540603 A JP 2006540603A JP 2007512299 A5 JP2007512299 A5 JP 2007512299A5
- Authority
- JP
- Japan
- Prior art keywords
- acetic acid
- alkyl
- pyrrolo
- pyridine
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 125000005843 halogen group Chemical group 0.000 claims description 18
- 125000001424 substituent group Chemical group 0.000 claims description 18
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- HWCXKAZEDDLUKC-UHFFFAOYSA-N 2-(4-iodo-3-quinolin-4-ylindazol-1-yl)acetic acid Chemical compound C12=C(I)C=CC=C2N(CC(=O)O)N=C1C1=CC=NC2=CC=CC=C12 HWCXKAZEDDLUKC-UHFFFAOYSA-N 0.000 claims 2
- GTPMZKSXYFJDBT-UHFFFAOYSA-N 2-(5-cyano-3-quinolin-4-ylindazol-1-yl)acetic acid Chemical compound C12=CC(C#N)=CC=C2N(CC(=O)O)N=C1C1=CC=NC2=CC=CC=C12 GTPMZKSXYFJDBT-UHFFFAOYSA-N 0.000 claims 2
- XCGNXVPVHVVNKB-UHFFFAOYSA-N 2-(5-methyl-3-quinolin-4-ylindazol-1-yl)acetic acid Chemical compound C1=CC=C2C(C3=NN(CC(O)=O)C4=CC=C(C=C43)C)=CC=NC2=C1 XCGNXVPVHVVNKB-UHFFFAOYSA-N 0.000 claims 2
- NMAWECDVPZADIN-UHFFFAOYSA-N 2-[2,5-dimethyl-3-(4-methylsulfonylphenyl)sulfanylpyrrolo[3,2-b]pyridin-1-yl]acetic acid Chemical compound C12=NC(C)=CC=C2N(CC(O)=O)C(C)=C1SC1=CC=C(S(C)(=O)=O)C=C1 NMAWECDVPZADIN-UHFFFAOYSA-N 0.000 claims 2
- KHUZDGNSFATQCD-UHFFFAOYSA-N 2-[2,5-dimethyl-3-[(4-methylsulfonylcyclohexa-2,4-dien-1-yl)methyl]pyrrolo[3,2-b]pyridin-1-yl]acetic acid Chemical compound C12=NC(C)=CC=C2N(CC(O)=O)C(C)=C1CC1CC=C(S(C)(=O)=O)C=C1 KHUZDGNSFATQCD-UHFFFAOYSA-N 0.000 claims 2
- IFGOUISYCKVYNY-UHFFFAOYSA-N 2-[2-methyl-3-(4-methylsulfonylphenyl)sulfanyl-4-phenylpyrrolo[3,2-c]pyridin-1-yl]acetic acid Chemical compound C12=C(C=3C=CC=CC=3)N=CC=C2N(CC(O)=O)C(C)=C1SC1=CC=C(S(C)(=O)=O)C=C1 IFGOUISYCKVYNY-UHFFFAOYSA-N 0.000 claims 2
- AYDMUJOILOMOQY-UHFFFAOYSA-N 2-[3-(4-chlorocyclohexa-2,4-dien-1-yl)sulfanyl-2,5-dimethylpyrrolo[3,2-b]pyridin-1-yl]acetic acid Chemical compound C12=NC(C)=CC=C2N(CC(O)=O)C(C)=C1SC1CC=C(Cl)C=C1 AYDMUJOILOMOQY-UHFFFAOYSA-N 0.000 claims 2
- JHOIZLRSVITTFP-UHFFFAOYSA-N 2-[3-(4-chlorophenyl)sulfanyl-2-methyl-4-phenylpyrrolo[3,2-c]pyridin-1-yl]acetic acid Chemical compound C12=C(C=3C=CC=CC=3)N=CC=C2N(CC(O)=O)C(C)=C1SC1=CC=C(Cl)C=C1 JHOIZLRSVITTFP-UHFFFAOYSA-N 0.000 claims 2
- JXCPHAXLKGDHBC-UHFFFAOYSA-N 2-[3-(4-chlorophenyl)sulfanyl-5-iodoindazol-1-yl]acetic acid Chemical compound C12=CC(I)=CC=C2N(CC(=O)O)N=C1SC1=CC=C(Cl)C=C1 JXCPHAXLKGDHBC-UHFFFAOYSA-N 0.000 claims 2
- JBBXNLYCRGAXTQ-UHFFFAOYSA-N 2-[3-(6-fluoroquinolin-4-yl)-4-(trifluoromethyl)indazol-1-yl]acetic acid Chemical compound C12=C(C(F)(F)F)C=CC=C2N(CC(=O)O)N=C1C1=CC=NC2=CC=C(F)C=C12 JBBXNLYCRGAXTQ-UHFFFAOYSA-N 0.000 claims 2
- CPJNKMYTZVMKCW-UHFFFAOYSA-N 2-[4-chloro-2-methyl-3-(4-methylsulfonylphenyl)sulfanylpyrrolo[3,2-c]pyridin-1-yl]acetic acid Chemical compound C12=C(Cl)N=CC=C2N(CC(O)=O)C(C)=C1SC1=CC=C(S(C)(=O)=O)C=C1 CPJNKMYTZVMKCW-UHFFFAOYSA-N 0.000 claims 2
- XEYDGQLGRXJVCH-UHFFFAOYSA-N 2-[4-chloro-3-(4-chlorophenyl)sulfanyl-2-methylpyrrolo[3,2-c]pyridin-1-yl]acetic acid Chemical compound C12=C(Cl)N=CC=C2N(CC(O)=O)C(C)=C1SC1=CC=C(Cl)C=C1 XEYDGQLGRXJVCH-UHFFFAOYSA-N 0.000 claims 2
- -1 3- (7-chloro-4-quinolinyl) -2-methyl-1H-pyrrolo [2,3-b] pyridine-1-acetic acid sodium salt Chemical compound 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 claims 2
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0303180A SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Novel compounds |
| PCT/GB2004/004937 WO2005054232A1 (en) | 2003-11-26 | 2004-11-24 | 1-acetic acid-indole, -indazole and-benzimidazole derivatives usful for the treatment of respiratory disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007512299A JP2007512299A (ja) | 2007-05-17 |
| JP2007512299A5 true JP2007512299A5 (https=) | 2007-12-06 |
Family
ID=29729190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006540603A Pending JP2007512299A (ja) | 2003-11-26 | 2004-11-24 | 呼吸器系疾患の処置に有用な１−酢酸−インドール、−インダゾールおよび−ベンズイミダゾール誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080027092A1 (https=) |
| EP (1) | EP1699781A1 (https=) |
| JP (1) | JP2007512299A (https=) |
| CN (1) | CN1906189A (https=) |
| SE (1) | SE0303180D0 (https=) |
| WO (1) | WO2005054232A1 (https=) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| SE0301569D0 (sv) * | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| JP4861976B2 (ja) * | 2004-03-11 | 2012-01-25 | アクテリオン ファーマシューティカルズ リミテッド | インドール−１−イル酢酸誘導体 |
| GB0412914D0 (en) * | 2004-06-10 | 2004-07-14 | Oxagen Ltd | Compounds |
| CA2594280C (en) | 2004-12-27 | 2013-04-23 | Anja Fecher | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists |
| GB0500604D0 (en) * | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
| DOP2006000016A (es) * | 2005-01-26 | 2006-07-31 | Aventis Pharma Inc | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2. |
| GB2422830A (en) * | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
| GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
| TW200720255A (en) | 2005-07-13 | 2007-06-01 | Taiho Pharmaceutical Co Ltd | Benzoimidazole compound capable of inhibiting prostaglandin d synthetase |
| JP5064219B2 (ja) * | 2005-07-22 | 2012-10-31 | 塩野義製薬株式会社 | Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体 |
| GB0525143D0 (en) * | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
| JP2009538289A (ja) * | 2006-05-26 | 2009-11-05 | アストラゼネカ・アクチエボラーグ | ビアリールまたはヘテロアリール置換インドール |
| WO2007149312A2 (en) | 2006-06-16 | 2007-12-27 | The Trustees Of The University Of Pennsylvania | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph |
| ATE530523T1 (de) | 2006-08-07 | 2011-11-15 | Actelion Pharmaceuticals Ltd | (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate |
| TW200831085A (en) * | 2006-12-13 | 2008-08-01 | Merck & Co Inc | Non-nucleoside reverse transcriptase inhibitors |
| DK2229358T3 (da) | 2007-12-14 | 2011-07-04 | Pulmagen Therapeutics Asthma Ltd | Indoler og deres terapeutiske anvendelse |
| US7750027B2 (en) * | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| EP2265581A1 (en) * | 2008-01-22 | 2010-12-29 | Oxagen Limited | Compounds having crth2 antagonist activity |
| JP2011509991A (ja) * | 2008-01-22 | 2011-03-31 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
| WO2009108551A2 (en) * | 2008-02-25 | 2009-09-03 | H. Lundbeck A/S | Heteroaryl amide analogues |
| US8138208B2 (en) | 2008-07-15 | 2012-03-20 | Hoffmann-La Roche Inc. | Aminotetrahydroindazoloacetic acids |
| EP2307382B1 (en) | 2008-07-15 | 2011-12-21 | F. Hoffmann-La Roche AG | Aminotetrahydroindazoloacetic acids |
| EP2321266A2 (en) | 2008-08-15 | 2011-05-18 | F. Hoffmann-La Roche AG | Substituted aminotetralines |
| EP2321268A2 (en) | 2008-08-15 | 2011-05-18 | F. Hoffmann-La Roche AG | Bi-aryl aminotetralines |
| RU2011124149A (ru) | 2008-11-17 | 2012-12-27 | Ф.Хоффманн-Ля Рош Аг | Нафтилуксусные кислоты |
| BRPI0921038A2 (pt) | 2008-11-17 | 2019-09-24 | Hoffmann La Roche | ácido naftilacéticos |
| CN102216273A (zh) | 2008-11-17 | 2011-10-12 | 霍夫曼-拉罗奇有限公司 | 用作crth2拮抗剂或部分激动剂的萘乙酸 |
| AU2009322836B2 (en) * | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP2392323A4 (en) * | 2009-01-30 | 2012-09-26 | Univ Kyoto | INHIBITOR OF PROSTATE CANCER PROGRESSION AND METHOD OF INHIBITING PROGRESSION |
| EP2533639A4 (en) | 2010-02-11 | 2013-08-21 | Univ Vanderbilt | PYRAZOLOPYRIDIN, PYRAZOLOPYRZIN, PYRAZOLOPYRIMIDIN, PYRAZOLOTHIOPHEN AND PYRAZOLOTHIAZOL COMPOUNDS AS ALLOSTERIC MGLUR4 POTENTRANS AND COMPOUNDS AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS |
| AR080703A1 (es) | 2010-03-22 | 2012-05-02 | Actelion Pharmaceuticals Ltd | Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma. |
| DE102011009961A1 (de) | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
| DK2697223T3 (en) | 2011-04-14 | 2016-09-05 | Actelion Pharmaceuticals Ltd | 7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor |
| EP2548863A1 (en) * | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
| US8470884B2 (en) | 2011-11-09 | 2013-06-25 | Hoffmann-La Roche Inc. | Alkenyl naphthylacetic acids |
| SG11201402796SA (en) | 2011-12-16 | 2014-06-27 | Atopix Therapeutics Ltd | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
| CN108938441A (zh) | 2012-03-21 | 2018-12-07 | 宾夕法尼亚大学理事会 | 用于调节毛发生长的组合物和方法 |
| PE20161177A1 (es) | 2014-03-17 | 2016-11-18 | Actelion Pharmaceuticals Ltd | Derivados del acido acetico azaindol y su uso como moduladores del receptor de prostaglandina d2 |
| WO2015140701A1 (en) | 2014-03-18 | 2015-09-24 | Actelion Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| JP6770522B2 (ja) | 2015-02-13 | 2020-10-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト |
| MX2018001217A (es) | 2015-07-30 | 2018-09-12 | Univ Pennsylvania | Alelos polimorficos de nucleotidos individuales del gen humano dp-2 para la deteccion de la susceptibilidad a la inhibicion del crecimiento del cabello por pgd2. |
| KR20180053345A (ko) | 2015-09-15 | 2018-05-21 | 이도르시아 파마슈티컬스 리미티드 | 결정질 형태 |
| TW201819361A (zh) * | 2016-09-03 | 2018-06-01 | 印度商托仁特生技有限公司 | 新穎吲唑化合物 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| CN108586311B (zh) * | 2018-03-23 | 2020-05-26 | 温州医科大学 | 一种3-硫醚吲哚或3-硒醚吲哚的制备方法 |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE790679A (fr) | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
| JPS5944312B2 (ja) * | 1974-11-22 | 1984-10-29 | 中外製薬株式会社 | インダゾ−ル誘導体の製法 |
| JPH0615542B2 (ja) * | 1986-07-22 | 1994-03-02 | 吉富製薬株式会社 | ピラゾロピリジン化合物 |
| US5095031A (en) * | 1990-08-20 | 1992-03-10 | Abbott Laboratories | Indole derivatives which inhibit leukotriene biosynthesis |
| JPH06206872A (ja) * | 1992-10-06 | 1994-07-26 | Yoshitomi Pharmaceut Ind Ltd | 縮合型ピラゾール化合物 |
| US5486525A (en) * | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
| US5567711A (en) * | 1995-04-19 | 1996-10-22 | Abbott Laboratories | Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists |
| US6916841B2 (en) * | 1998-02-25 | 2005-07-12 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| CN1420882A (zh) | 1999-07-28 | 2003-05-28 | 阿温蒂斯药物公司 | 取代的氧代氮杂杂环基化合物 |
| WO2001047922A2 (en) * | 1999-12-24 | 2001-07-05 | Aventis Pharma Limited | Azaindoles |
| US6878522B2 (en) * | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| US6506738B1 (en) * | 2000-09-27 | 2003-01-14 | Bristol-Myers Squibb Company | Benzimidazolone antiviral agents |
| TWI317634B (en) * | 2001-12-13 | 2009-12-01 | Nat Health Research Institutes | Aroyl indoles compounds |
| SE0200356D0 (sv) * | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200411D0 (sv) * | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| AU2003231509A1 (en) * | 2002-05-16 | 2003-12-02 | Shionogi And Co., Ltd. | Compound exhibiting pgd 2 receptor antagonism |
| TW200307542A (en) * | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0201635D0 (sv) * | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) * | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| SE0301569D0 (sv) * | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| SE0302232D0 (sv) * | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| GB0500604D0 (en) * | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
| JP2009538289A (ja) * | 2006-05-26 | 2009-11-05 | アストラゼネカ・アクチエボラーグ | ビアリールまたはヘテロアリール置換インドール |
-
2003
- 2003-11-26 SE SE0303180A patent/SE0303180D0/xx unknown
-
2004
- 2004-11-24 JP JP2006540603A patent/JP2007512299A/ja active Pending
- 2004-11-24 CN CNA2004800409412A patent/CN1906189A/zh active Pending
- 2004-11-24 WO PCT/GB2004/004937 patent/WO2005054232A1/en not_active Ceased
- 2004-11-24 US US10/580,576 patent/US20080027092A1/en not_active Abandoned
- 2004-11-24 EP EP04798644A patent/EP1699781A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007512299A5 (https=) | ||
| JP2013539789A5 (https=) | ||
| JP2004536869A5 (https=) | ||
| JP2007519649A5 (https=) | ||
| JP2005538100A5 (https=) | ||
| JP2005535586A5 (https=) | ||
| JP2014526501A5 (https=) | ||
| JP2014526500A5 (https=) | ||
| JP2003511384A5 (https=) | ||
| JP2006517572A5 (https=) | ||
| JP2014532626A5 (https=) | ||
| JP2005508967A5 (https=) | ||
| IL159257A (en) | Substituted oxazolidinones for combinational therapy, their preparation and pharmaceutical compositions comprising them | |
| JP2007520440A5 (https=) | ||
| JP2007507494A5 (https=) | ||
| JP2006515339A5 (https=) | ||
| RU2015121043A (ru) | Производные фенилэтилпиридина в качестве ингибиторов PDE-4 | |
| RU2007101236A (ru) | Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей | |
| JP2005530811A5 (https=) | ||
| JP2006516626A5 (https=) | ||
| JP2005537323A5 (https=) | ||
| RU2006130000A (ru) | Органические соединения | |
| JP2017501983A5 (https=) | ||
| JP2005538111A5 (https=) | ||
| JP2019520344A5 (https=) |